Skip to content

Progyny PGNY Free cash flow

Free cash flow at other companies

CVS Health logo
CVS HealthCVS
$3.4B-10.8%
UnitedHealth Group logo
UnitedHealth GroupUNH
$8.15B+78.8%
Natera, Inc. logo
Natera, Inc.NTRA
$18.03M-20.3%
Pediatrix Medical Group logo
Pediatrix Medical GroupMD
-$136.09M-12.7%
Organon logo
OrganonOGN
$188M+337%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$10.96M+3,842%

Other financials

Income statement

See full
Revenue$328.5M+1.4%
Gross profit$83.1M+9.6%
Operating income$35.4M+46.4%
Net income$24.2M+60.9%
EPS (diluted)$0.29+70.6%

Balance sheet

See full
Cash & equivalents$131.6M+20.5%
Total debt$27.3M-5.6%
Total equity$439.3M-6.0%
Total assets$698.3M-4.4%

Cash flow

See full
Operating cash flow$45.9M-7.7%
CapEx$6.3M+123%

Valuation

See full
Market cap$2.09B-27.1%
Enterprise value$1.98B-29.6%
P/E30.8×-23.7×
P/S1.6×-0.7×

Profitability

See full
Gross margin24.1%+2.1pp
Operating margin7.5%+1.4pp
Net margin5.2%+0.9pp
FCF margin14.3%-1.9pp

Returns & leverage

See full
Return on equity14.9%+4.8pp
Debt / equity0.1×0.0×
Current ratio2.1×-0.3×

Where this comes from

Calculated from Progyny’s reported figures.

The official record: Progyny’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Progyny's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Progyny's free cash flow?
Progyny (PGNY) reported free cash flow of $39.6M in Q1 2026.
How has Progyny's free cash flow changed year-over-year?
Progyny's free cash flow decreased by 15.7% year-over-year, from $46.97M to $39.6M.
What is the long-term trend for Progyny's free cash flow?
Over 4 years (2021 to 2025), Progyny's free cash flow has grown at a 68.3% compound annual growth rate (CAGR), from $23.91M to $191.78M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.